What is ?
Vitaflo® has worked with leading metabolic centers, scientists and individuals with GSD in the development of Glycosade®, a modified slow-release starch that can help keep blood sugar levels normal for longer and prevent low blood sugar (hypoglycemia).
How does work?
A constant supply of glucose is required to keep blood sugar levels normal. Glycosade is made from a very special type of cornstarch that will be slowly digested and produce glucose for several hours.
How do you take your ?
Glycosade must only be started after consulting with your healthcare professional.
- Glycosade can be mixed and taken in the same way as your current uncooked cornstarch (UCCS).
- Always consult with your doctor or dietitian before changing your dose.
- Glycosade is suitable for use from 5 years of age in the United States.
- Slowly digested starch 
- Slower release of glucose
- Greater spacing between starch doses
- May eliminate need for nocturnal continuous enteral feed
- Maintains normoglycemia for longer  
- Improved duration compared to standard cornstarch therapy
- Slower rise and fall in blood glucose level
- Effective as a night time feed as it prolongs normoglycemia and allows for longer sleep period
- May reduce plasma insulin response  
- Avoidance of hyperinsulinism
- Improves appetite  
- Promotes hunger for normal food
- May prevent excessive weight gain
- Increases flexibility in lifestyle
- Mealtime enjoyment
- Reduced colonic fermentation 
- May indicate improved digestibility and reduced GI symptoms
- Improves quality of life 
Talk to your Healthcare Professional
Glycosade must only be started after consulting with your healthcare provider. Speak to your healthcare provider to learn more about Glycosade and find out if it may be appropriate for you.
View full datasheet.
For dosage and administration, please consult your healthcare professional.
 Correia CE, Bhattacharaya K, Lee PJ, Shuster JJ, Thriaque DW, Shankar MN, Smit PA, Weinstein DA. Use of modifi ed cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. American Journal of Clinical Nutrition (2008) 88: 1272-6.
 Bhattacharya K, Orton RC, Qi X, Mundy H, Morley DW, Champion MP, Eaton S, Tester RF, Lee PJ. A novel starch for the treatment of glycogen storage diseases. Journal of Inherited Metabolic Disease (2007) 30: 350-7.
 Maritz CM, Cousins A, Murphy E. Reduction in insulin response in a patient with GSD1 using a new modified starch: Case report. Molecular Genetics and Metabolism (2009) 98: 39.
 Humphrey MS. The use of Glycosade™ to extend fasting tolerance and improve oral intake in GSD1b. Molecular Genetics and Metabolism (2009) 98:116.
 Mullally M, Mundy H, Champion M, Gick J, Eardley J, Emery P. Retrospective Evaluation of Clinical Practice: Using a Modified Cornstarch in the Management of Glycogen Storage Disease. Journal of Inherited Metabolic Disease (2010) 33(Suppl 1): S72.